ResultsIQ › Latest results › Acutaas Chemicals Limited
Acutaas Chemicals Limited Q2 FY27 earnings call summary
NSE: ACUTAAS · BSE: 543349
Earnings call of 27 Oct 2026, summarised by AI from the filing.
Acutaas Q2 FY27 revenue rose 42.7% to ₹4,369 million and it raised FY27 guidance to around 30% growth and 38%-40% EBITDA margin.
Key takeaways
- Guidance FY27 revenue growth guidance raised to around 30% and EBITDA margin to 38%-40%.
- CDMO pull-forward CDMO revenue target of ₹1,000 cr now expected in FY27, one year ahead of schedule.
- Pharma driver Pharma intermediates revenue ₹4,020 million, up 53.1%, on CDMO growth and new product ramp-up.
- Specialty drag Specialty Chemical revenue ₹349 million, down 20% Y-o-Y on legacy phase-out and the BFC shipment pause.
Acutaas Chemicals Limited Q2 FY27 results
As filed: Revenue ₹437 cr (+43% year on year), EBITDA ₹176 cr (+85% year on year), PAT ₹123 cr (+71% year on year), EBITDA margin 40.3% (+923 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹330 cr (+59% year on year), EBITDA ₹113 cr (+122% year on year), PAT ₹75.0 cr (+70% year on year), EBITDA margin 34.3% (+966 bps). Score 85 of 100, Above trend. EBITDA margin rose 966 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 24% from last quarter. Share price after the results: −8.4% in 28 days (Nifty 500: +2.4%).
- Q4 FY26: Revenue ₹422 cr, EBITDA ₹181 cr, PAT ₹137 cr, EBITDA margin 43.0%. Not scored. No result for the same quarter last year. Share price after the results: +25.2% in 29 days (Nifty 500: −0.9%).
- Q3 FY26: Revenue ₹391 cr, EBITDA ₹154 cr, PAT ₹112 cr, EBITDA margin 39.5%. Not scored. No result for the same quarter last year. Share price after the results: +30.9% in 30 days (Nifty 500: +1.5%).
- Q2 FY26: Revenue ₹305 cr, EBITDA ₹97.0 cr, PAT ₹73.0 cr, EBITDA margin 31.8%. Not scored. No result for the same quarter last year. Share price after the results: +10.2% in 28 days (Nifty 500: +1.2%).
- Q1 FY26: Revenue ₹206 cr, EBITDA ₹51.0 cr, PAT ₹45.0 cr, EBITDA margin 24.8%. Not scored. No result for the same quarter last year. Share price after the results: +20.5% in 30 days (Nifty 500: −2.4%).
Past price moves after results do not indicate future moves. Not a recommendation.
Acutaas Chemicals Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (27 Oct 2026), Results deck (27 Oct 2026), Results press release (27 Oct 2026)
- Q1 FY27: Earnings call (24 Jul 2026), Results deck (24 Jul 2026), Results press release (24 Jul 2026)
- Q4 FY26: Earnings call (30 Apr 2026), Results deck (30 Apr 2026), Results press release (30 Apr 2026)
- Q3 FY26: Earnings call (28 Jan 2026), Results deck (28 Jan 2026), Results press release (28 Jan 2026)
- Q2 FY26: Earnings call (17 Oct 2025), Results deck (17 Oct 2025), Results press release (17 Oct 2025)
- Q1 FY26: Earnings call (30 Jul 2025), Results deck (30 Jul 2025)
- Q4 FY25: Earnings call (2 May 2025), Results deck (2 May 2025), Results press release (2 May 2025)
- Other events: Strategy deck (16 May 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.